Notably, sorafenib achieves tumor angiogenesis inhibition by targeting the hepatocyte cytokine receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor 2 (VEGFR-2) (5). Here, KDR is linked to neoplasm.